• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by CureVac N.V. (Amendment)

    2/14/24 5:01:40 PM ET
    $CVAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CVAC alert in real time by email
    SC 13G/A 1 tm246065d7_sc13ga.htm SC 13G/A

     

      

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    WASHINGTON, D.C. 20549

     

    ______________

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    CUREVAC N.V. 

    (Name of Issuer)

     

    Common Shares, nominal value £0.12 per share
    (Title of Class of Securities)

     

    N2451R105 

    (CUSIP Number)

     

    December 31, 2023 

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b) 

    xRule 13d-1(c) 

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. N2451R105

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Management, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0 

    6

    SHARED VOTING POWER

     

    2,744,270

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    2,744,270

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,744,270

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

      

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    1.2%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

     

     

     

     

      

    CUSIP No. N2451R105

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Peter Kolchinsky

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

      

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    2,744,270

    7

    SOLE DISPOSITIVE POWER

     

    0 

    8

    SHARED DISPOSITIVE POWER

     

    2,744,270

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,744,270

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    1.2%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN, HC

     

     

     

     

     

    CUSIP No. N2451R105

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Rajeev Shah

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    2,744,270

    7

    SOLE DISPOSITIVE POWER

     

    0 

    8

    SHARED DISPOSITIVE POWER

     

    2,744,270

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,744,270

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    1.2%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN, HC

     

     

     

     

     

    CUSIP No. N2451R105

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Healthcare Fund, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    2,744,270

    7

    SOLE DISPOSITIVE POWER

     

    0 

    8

    SHARED DISPOSITIVE POWER

     

    2,744,270

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,744,270

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    1.2%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

     

     

     

     

    Item 1(a). Name of Issuer:

     

      CureVac N.V. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany

     

    Item 2(a).Names of Persons Filing:

     

    The names of the persons filing this report (collectively, the “Reporting Persons”) are: 

    RA Capital Management, L.P. (“RA Capital”) 

    Peter Kolchinsky 

    Rajeev Shah 

    RA Capital Healthcare Fund, L.P. (the “Fund”)

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is: 

    c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c).Citizenship:

     

    RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d).Title of Class of Securities:

     

    Common Shares, nominal value £0.12 per share (“Common Shares”)

     

    Item 2(e).CUSIP Number:

     

    N2451R105  

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4.Ownership.

     

    The Fund directly holds 2,744,270 Common Shares.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G/A. The beneficial ownership percentages reported are based on the equivalent of 223,923,708 outstanding Common Shares, as reported in the Issuer’s Form 6-K filed on November 14, 2023, with the Securities and Exchange Commission.

     

     

     

     

    RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the Issuer’s Common Shares reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G/A shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ⌧.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    Exhibit List

     

    Exhibit 1: Joint Filing Agreement

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:     February 14, 2024

     

    RA CAPITAL MANAGEMENT, L.P.

     

    By: /s/ Peter Kolchinsky  
    Name:  Peter Kolchinsky  
    Title:   Authorized Signatory  

     

    PETER KOLCHINSKY

     

    /s/Peter Kolchinsky  

     

    RAJEEV SHAH

     

    /s/Rajeev Shah  

     

    RA CAPITAL HEALTHCARE FUND, L.P.

     

    By: RA Capital Healthcare Fund GP, LLC  
    Its: General Partner  

     

    By: /s/ Peter Kolchinsky  
    Name:  Peter Kolchinsky  
    Title:   Manager  

     

     

    Get the next $CVAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVAC

    DatePrice TargetRatingAnalyst
    6/13/2025$5.00Buy → Hold
    Jefferies
    4/25/2024$12.00 → $4.00Outperform → Market Perform
    Leerink Partners
    6/8/2023$13.00Outperform
    SVB Securities
    1/19/2023$8.00 → $18.00Neutral → Buy
    UBS
    1/9/2023$9.00 → $21.00Hold → Buy
    Jefferies
    1/21/2022$55.00 → $20.00Neutral → Underperform
    B of A Securities
    1/18/2022$52.00Market Outperform
    JMP Securities
    10/22/2021$35.00Hold
    Deutsche Bank
    More analyst ratings